clinical trial · NCT07439653
A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma
TORL Biotherapeutics, LLC·phase2·recruiting·n = 155
Histologically Confirmed Relapsed or Refractory B-cell Non-Hodgkin LymphomaTORL-5-700TORL-5-700 at MTD/RP2DTORL-5-700 at MTD/RP2D in combination with another agent
brief summary
A Phase 1/2 study to evaluate safety, tolerability, and anticancer activity of TORL-5-700 as a monotherapy and in combination in R/R NHL
started
Mar 31, 2026
primary completion
Mar 31, 2029
completion
Sep 30, 2029
last updated
Jun 11, 2026
official title
A Phase 1/2, First-in-Human, Open-Label, Multicenter Study of TORL-5-700 as a Monotherapy and in Combination for Participants With Relapsed or Refractory Non-Hodgkin Lymphoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol